Bispecific Antibody-mediated Target Cell-specific Costimulation of Resting T Cells via CD5 and CD28

Cancer Research

Volumn 55, Issue 19, 1995, Pages 4409-4415

  Kroesen, Bart Jan ^a   Bakker, Annie ^a   The, Hauw T ^a   de Leij, Lou ^a   van Lier, Rene A W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CD69 ANTIGEN; EPITHELIAL GLYCOPROTEIN 2; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD5; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0029144606     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Staerz, U. D., Kanagawa, O., and Bevan, M. J. Hybrid antibodies can target sites for attack by T cells. Nature (Lond.), 314: 628–631, 1985.
2. Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., and Segal, D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature (Lond.), 316: 354–356, 1985.
3. Phillips, J. H., and Lanier, L. L. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. J. Immunol., 136: 1579–1585, 1986.
4. de Jong, R., Brouwer, M., Rebel, V. I., van Seventer, G. A., Miedema, F., and van Lier, R. A. W. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation. Immunology, 70: 357–364, 1990.
5. Weiner, G. J., Kostelny, S. A., Hillstrom, J. R., Cole, M. S., Link, B. K., Wang, S. L., and Tso, J. Y. The role of T cell activation in anti-CD3 X antitumor bispecific antibody therapy. J. Immunol., 152: 2385–2392, 1994.
6. Penna, C., Dean, P. A., and Nelson, H. Antitumor X anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with Staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res., 54: 2738–2743, 1994.
7. van Wauwe, J. P., de Mey, J. R., and Gossens, J. G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent autogenic properties. J. Immunol., 124: 2708–2713, 1980.
8. Palacios, R. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody. Eur. J. Immunol., 15: 645–651, 1985.
9. Janssen, R. A. J., Heijn, A. A., The, T. H., and De Leij, L. Poor induction of IL-2R expression on CD8 bright cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb. Cancer Immunol. Immunother., 38: 53–60, 1994.
10. Bloemena, E., Roos, M. T., Van Heijst, J. L., Vossen, J. M., and Schellekens, P. T. Whole-blood lymphocyte cultures. J. Immunol. Methods, 722: 161–167, 1989.
11. Buter, J., Janssen, R. A. J., Martens, A., Sleijfer, D. T., De Leij, L., and Mulder, N. H. Phase I/II study of low dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. Eur. J. Cancer, 29: 2108–2113, 1993.
12. Sosman, J. A., Weiss, G. R., Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., O'Boyle, K., Fisher, S. G., Mier, J., Vachino, G., and Caliendo, G. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J. Clin. Oncol., 11: 1496–1505, 1993.
13. Janssen, R. A. J., Buter, J., Straatsma, E., Heijn, A. A., Sleijfer, D. T., De Vries, E. G. E., Mulder, N. H., The, T. H., and De Leij, L. HLA-Dr-expressing CD8 bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Cancer Immunol. Immunother., 36: 198–204, 1993.
14. van Seventer, G. A., Shimizu, Y., Horgan, K. J., Luce, G. E., Webb, D., and Shaw, S. Remote T cell co-stimulation via LFA-l/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation. Eur. J. Immunol., 21: 1711–1718, 1991.
15. Chong, A. S., Jiang, X. L., Scuderi, P., Lamas, M., and Graf, L. H., Jr. ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon y production in interleukin-2-activated T cells. Cancer Immunol. Immunother., 39: 127–134, 1994.
16. Kuiper, H. M., de Jong, R., Brouwer, M., and Lammers, K. Influence of CD28 co-stimulation on cytokine production is mainly regulated via interleukin-2. Immunology, 83: 38, 1994.
17. June, C. H., Ledbetter, J. A., Linsley, P. S., and Thompson, C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today, 11: 211–216, 1990.
18. Vandenberghe, P., Verwilghen, J., van Vaeck, F., and Ceuppens, J. L. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology, 78: 210–217, 1993.
19. Bohlen, H., Manzke, O., Titzer, S., Engert, A., Wolf, J., Diehl, V., and Tesch, H. Treatment of EB-virus induced B-cell LCL in SCID-HU mice using CD3 X CD19 bispecific and CD28 antibodies. Proc. Am. Assoc. Cancer Res., 35: 510, 1994.
20. Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dorken, B., von Fliedner, V., Diehl, V., and Tesch, H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res., 53: 4310–4314, 1993.
21. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Trumper, L., Hartmann, F., Diehl, V., van Lier, R., and Pfreundschuh, M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (Washington DC), 264: 833–835, 1994.
22. Chen, L., Linsley, P. S., and Hellstrdm, K. E. Costimulation of T cells for tumor immunity. Immunol. Today, 14: 483–486, 1993.
23. Chen, L., Ashe, S., Brady, W. A., HellstrSm, K. E., Ledbetter, J. A., McGowna, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093–1102, 1992.
24. June, C. H., Rabinovitch, P. S., and Ledbetter, J. A. CD5 antibodies increase intracellular ionized calcium concentration in T cells. J. Immunol., 138: 2782–2792, 1987.
25. Ceuppens, J. L., and Baroja, M. L. Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3. J. Immunol., 137: 1816–1821, 1986.
26. Ledbetter, J. A., Martin, P. J., Spooner, C. E., Wofsy, D., Tsu, T. T., Beatty, P. G., and Gladstone, P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J. Immunol., 755: 233, 1985.
27. Mellstedt, H., Frodin, J. E., Masucci, G., Ragnhammer, P., Fagerberg, J., Hjelm, A. L., Shetye, J., Wersall, P., and Osterborg, A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin. Oncol., 78: 462–477, 1991.
28. Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A. J., van der Graaf, W., The, T. H., De Leij, L., and Mulder, N. H. Phase I study of intravenously applied bispecific antibody in patients receiving subcutaneous IL-2. Br. J. Cancer, 70: 652–661, 1994.
29. Kroesen, B. J., ter Haar, A., Spakman, H., Willemse, P., Sleijfer, D. T., de Vries, E. G., Mulder, N. H., Berendsen, H. H., Limburg, P. C., The, T. H., and De Leij, L. Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody-redirected T cells. Cancer Immunol. Immunother., 37: 400–407, 1993.
30. Hamblin, A., Taylor, M., Bernhagen, J., Shakoor, Z., Mayall, S., Noble, G., and McCarthy, D. A method of preparing blood leucocytes for flow cytometry which prevents upregulation of leucocyte integrins. J. Immunol. Methods, 146: 219–228,1992.
31. De Leij, L., Postmus, P. E., Buys, H. C. M., Elema, J. D., Ramaekers, F., Poppema, S., Brouwer, M., van der Veen, A. Y., Mesander, G., and The, H. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res., 45: 6024–6033, 1985.
32. Tax, W. J. M., Willems, H. W., Reekers, P. P. M., Capel, P. J., and Koene, R. A. P. Polymorphism in mitogenic effect of IgGl monoclonal antibodies against T3 antigen on human T cells. Nature, 304: 445–447, 1983.
33. de Lau, W. J. M., van Loon, A. E., Heije, K., Valerio, D., and Bast, B. J. Production of hybrid hybridomas on HAT sensitive neomicin resistant double mutants. J. Immunol., 777: 1–8, 1989.
34. De Leij, L., Helfrich, W., Stein, R., and Mattes, M. J. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer, S8: 60–63, 1994.
35. van Lier, R. A. W., Brouwer, M., de Jong, R., Groot, M., de Groot, E. R., and Aarden, L. A. Leucocyte typing IV, p. 353. Oxford, England: Oxford University Press, 1989.
36. Janssen, R. A. J., Kroesen, B. J., Buter, J., Mesander, G., Sleijfer, D. T., The, T. H., Mulder, N. H., and De Leij, L. Immunomodulatory effects of intravenous BIS-1 F(ab’)2 administration in renal cell cancer patients. Br. J. Cancer, in press, 1995.
37. Verwilghen, J., Vandenberghe, P., Wallays, G., de Boer, M., Anthony, N., Panayi, G. S., and Ceuppens, J. L. Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J. Immunol., 750: 835–846, 1993.
38. Ledbetter, J. A., June, C. H., Martin, P. J., Spooner, C. E., and Hansen, J. A. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C., cytoplasmic free calcium, and proliferation. J. Immunol., 756: 3945–3952, 1986.
39. Schwartz, R. H. A cell culture model for T lymphocyte clonal anergy. Science (Washington DC), 248: 1349–1356, 1990.
40. Swoboda, R., Bommhardt, U., and Schimpl, A. Regulation of lymphokine expression in T cell activation. I. Rapid loss of interleukin-specific RNA after removal of the stimulating signal. Eur. J. Immunol., 27: 1691–1695, 1991.
41. Lindsten, T., June, C. H., Ledbetter, J. A., Stella, G., and Thompson, C. B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (Washington DC), 244: 339–343, 1989.
42. Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 71:1065–1068,1992.
43. Ledbetter, J. A., Parsons, M., Martin, P. J., Hansen, J. A., Rabinovitch, P. S., and June, C. H. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J. Immunol., 757: 3299–3305, 1986.
44. Spertini, F., Stohl, W., Ramesh, N., Moody, C., and Geha, R. S. Induction of human T cell proliferation by a monoclonal antibody to CD5. J. Immunol., 146:47–52,1991.
45. Gajewski, T. F., Qian, D., Fields, P., and Fitch, F. W. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase pathways. Proc. Natl. Acad. Sci. USA, 97: 38–42, 1994.